Substance Use Disorders Management Boot Camp (October 15-16, 2026)

De Pere, WI US
October 15, 2026 to October 16, 2026

Overview 

This training aims to enhance confidence and competencies related to the management of substance use disorders in general medical settings. Through case-based and interactive didactic content, the workshop will explore issues related to assessment, monitoring, prevention, and management in the setting of unhealthy substance use.

Intended Audience

This program is designed for physicians, physician assistants, nurses, advanced practice nurses, pharmacists, social workers, pre-hospital providers, students, residents, and fellows who treat patients with opioid use disorder.

Learning Objectives

As a result of participating in this activity, learners, as members of the healthcare team, will be able to: 

  1. Determine accurate diagnosis and initiate treatment for opioid use disorder, alcohol withdrawal, and alcohol use disorder                    
  2. Demonstrate medical management and brief counseling skills needed to to work with patients who continue to use drugs and alcohol while in treatment for use disorder                  
  3. Determine appropriate treatment plan for OUD and AUD, including the initiation and maintenance of buprenorphine therapy, alcohol withdrawal management, and MAUD.  
  4. Develop approaches to working with and managing patients with stimulant use disorders and/or Hepatitis C.

Elements of Competence

This educational activity is designed to change learner competence and focuses on the following competencies:

  • Accreditation Council for Graduate Medical Education (ACGME)/Nursing: Patient care and procedural skills, medical knowledge, interpersonal and communication skills, and professionalism.
  • National Academy of Medicine (NAM)/Nursing: Provide patient/person-centered care, employ evidence-based practice, population health
  • Interprofessional Education Collaborative Competencies: Values/ethics for interprofessional practice, roles and responsibilities, communication, and teams and teamwork
  • Social Impact and Belonging: Values and ethics, Roles and Responsibilities, Communication, Teams and Teamwork

Course summary

Available credit: 
  • 9.75 AAPA Category 1 CME
  • 9.75 ACPE Contact Hours - Pharmacist
  • 9.75 ACPE Contact Hours - Pharmacist Technician
  • 9.75 AMA PRA Category 1 Credit™
  • 9.75 ANCC Contact Hours
    • 9.75 Wisconsin Responsible Opioid Prescribing Credit
    • 2.75 ANCC Pharmacotherapy Contact Hours
  • 9.75 University of Wisconsin–Madison Continuing Education Hours
    • 9.75 Approved for AMA PRA Category 1 Credit™
    • 9.75 Wisconsin Responsible Opioid Prescribing Credit
Registration opens: 
08/14/2026
Course expires: 
11/30/2026
Event starts: 
10/15/2026 - 8:30am CDT
Event ends: 
10/16/2026 - 2:30pm CDT
Cost:
$0.00
Add to calendar: 
Rating: 
0

Agenda

Thursday, October 15

TimeActivity
8:00 a.m.

Breakfast/ Welcome/ Introductions

9:00 a.m.

Diagnosis and Overview of MOUD

Jillian Landeck, MD

10:30 a.m.

Break

10:40 a.m.

Low Dose / High Dose Initiation

Jillian Landeck, MD

12:00 p.m.

Lunch

12:45 p.m.

Extended-Release Buprenorphine Products 

David Leinweber, MD

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Describe the differences between the Sublocade and Brixadi.
  2. Discuss the pharmacokinetics of extended-release buprenorphine products.
  3. Explain how to administer and initiate extended-release buprenorphine products.
     
1:30 p.m.

Motivational Interviewing: An Intervention in Words

Julia Yates, LCSW

Upon completion of this educational activity, members of the healthcare team will be able to:

1.    List 3 key elements of the spirit of motivational interviewing.
2.    Describe and provide examples of the stages of change.
3.    Practice identifying and listening for change talk using the DARNs.
4.    Recognize and practice using the core skills of motivational interviewing from the OARS took-kit.

2:30 p.m.

Break

2:45 p.m.

Approaches to Buprenorphine for Chronic Pain

Margaret Gray, MD

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. List commercially available buprenorphine products for pain and opioid use disorder (OUD)
  2. Evaluate which patients are appropriate chronic pain management with buprenorphine and be able discuss the medication’s strengths and limitations in  patient-centered terms
  3. Create a transition strategy from full mu-opioid agonists to buprenorphine
  4. Make recommendations for management of acute on chronic pain in patients using buprenorphine for pain and/or OUD
4:15 p.m.

Questions, wrap up

4:30 p.m.

Close

Friday, October 16

TimeActivity
8:00 a.m.

Breakfast

8:30 a.m.

Medical Management of Alcohol Withdrawal and Alcohol Use Disorders

Randy Brown, MD, PHD, DFASAM

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Diagnose and determine the severity of alcohol use disorder or alcohol misuse
  2. Determine appropriate environment (inpatient vs. outpatient) and medication for withdrawal management
  3. Select medications to reduce alcohol use and craving in patients with alcohol use disorder
9:45 a.m.

Harm Reduction Services

All faculty

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Define the core principals of harm reduction.
  2. Recognize harmful instances of stigma towards individuals with substance use disorders in healthcare settings.
  3. Provide examples of harm reduction equipment used by patients with SUD.
10:45 a.m.

Break

11:00 a.m.

Stimulant Use Disorder 

David Leinweber, MD

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Describe the key clinical features of stimulant use disorder and summarize the major recommendations from the ASAM Stimulant Use Disorder guidelines
  2. Compare and contrast the mechanisms of action of cocaine and methamphetamine
  3. Identify at least three off-label pharmacologic treatments for amphetamine type stimulant use disorder and/or cocaine use disorder
11:30 a.m.

Urine Drug Screens

David Leinweber, MD

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Identify common limitations of immunoassay urine drug screening, including at least three causes of false positive and/or false negative results
  2. Differentiate between screening (immunoassay) and confirmatory urine drug testing
  3. Interpret expected and unexpected urine drug screens and how to appropriately management results with patients  
     
12:00 p.m.

Lunch

12:30 p.m.

Deprescribing Benzodiazepines (BZs) in Primary Care

Randy Brown, MD, PHD, DFASAM

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Discuss the potential risks and benefits of long-term benzodiazepines.
  2. Identify patients at risk for significant withdrawal symptoms in the setting of BZ discontinuation
  3. Develop plans for BZ taper and appropriate patient support to enhance patient comfort
1:00 p.m.

Peer Support and Recovery

All faculty

Upon completion of this educational activity, members of the healthcare team will be able to:

  1. Describe the fundamental principles of peer support and recovery.
  2. Identify ways peer support services can assist patients in coordination with healthcare providers.
     
1:45 p.m.

Wrap up 

Provided by

  • University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)
    • UW-Madison School of Medicine and Public Health
  • Wisconsin Department of Health Services
  • Wisconsin Partnership Program
Bemis Conference Center
299 Third Street
De Pere, WI 54115
United States

For additional questions, please contact Kathleen Maher, [email protected]. 

Learners are responsible for their own transportation and lodging. The planners have recommended the following option for lodging:

Kress Inn, Ascend Hotel Collection
300 Grant Street, De Pere, WI, 54115, USA
Phone +1-920-403-5100
Toll Free +1-800-221-5070
Fax +1-920-403-5198

Planners and Faculty

NameRoleTitle/Affiliation
Margaret Gray, MDPlanning Committee Member, FacultyAssistant Professor, Department of Family Medicine and Community Health 
David Leinweber, MDPlanning Committee Member, FacultyAssistant Professor, Department of Family Medicine and Community Health
Maggie Williams, MPAS, PA-C, CPAAPAPlanning Committee Member, FacultyAddiction Medicine Physician Assistant, UW Health
Jillian Landeck, MDFacultyAssociate Professor (CHS), Department of Family Medicine and Community Health
Jill Lindwall, RNPlanning Committee MemberClinical Staff Educator at University of Wisconsin Medical Foundation
Cody Wenthur, PharmD, PhDPlanning Committee MemberDirector, MS Program in Psychoactive Pharmaceutical Investigation, ExecComm, Transdisciplinary Center for Research in Psychoactive Substances, University of Wisconsin - Madison
Kathleen Maher, BAActivity CoordinatorOutreach Program Manager, PROTEA
Kelly Eagen, MDPlanning Committee Member, FacultyAssistant Professor, Department of Family Medicine and Community Health, Associate Program Director, Addiction Medicine Fellowship, UW-Madison School of Medicine and Public Health
Randy Brown, MD, PHD, DFASAMClinical Director/Planning Committee Chair, FacultyPROTEA Director, Professor, UW School of Medicine & Public Health
Julia Yates, LCSWFacultyDirector of Behavioral Health and Wellbeing Program Manager, Department of Family Medicine and Community Health, University of Wisconsin Madison
James Eberhard, MFA, Accreditation SpecialistContinuous Certification and Cont Edu. Prgm Mgr, Office of Continuing Professional Development, UW-Madison School of Medicine and Public Health

Policy on Disclosure

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence the content of this accredited continuing education (CE).  In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.

For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below:

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.

NameRoleRelevant Financial Relationships DisclosedDiscussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation?
Kelly Eagen, MDPlanning Committee Member, FacultyNo relevant relationships with ineligible companies to discloseNo
Margaret Gray, MDPlanning Committee Member, FacultyNo relevant relationships with ineligible companies to discloseYes
David Leinweber, MDPlanning Committee Member, FacultyNo relevant relationships with ineligible companies to discloseNo
Maggie Williams, MPAS, PA-C, CPAAPAPlanning Committee Member, FacultyNo relevant relationships with ineligible companies to discloseNo
Jill Lindwall, RNPlanning Committee MemberNo relevant relationships with ineligible companies to discloseNo
Cody Wenthur, PharmD, PhDPlanning Committee MemberPalomar Labs (Independent Contractor - Consultant)No
Randy Brown, MD, PHD, DFASAMClinical Director/Planning Committee Chair, FacultyNo relevant relationships with ineligible companies to discloseYes
Kathleen Maher, BAActivity CoordinatorNo relevant relationships with ineligible companies to discloseNo
James Eberhard, MFAAccreditation SpecialistNo relevant relationships with ineligible companies to discloseNo
Discloser List CME Internal Report

Accreditation and Credit Designation Statements

Accreditation Logos

Accreditation Statements

Joint Accreditation with Commendation LogoIn support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison ICEP and the Wisconsin Department of Health Services. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 9.75 ANCC contact hours, X.X of which are eligible for pharmacotherapeutic contact hours.

AAPA Credit Logo

American Academy of Physician Assistants (AAPA)

The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

 

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 9.75 hours. Credit can be earned by documented attendance and completing an activity evaluation form. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. 

Universal Activity Number (UAN): JA0000358-XXXX-YR-XXX-LXX-P; JA0000358-XXXX-YR- XXX-LXX-T

 

Wisconsin Medical Examining Board Opioid CME

This course is approved by the Wisconsin Medical Examining Board as meeting the requirements for a continuing education course on the responsible opioid prescribing guidelines per Med 13.03(3) of the Wisconsin Administrative Code.

Course Title: Substance Use Disorders Management Boot Camp (October 15-16, 2026)
The following instructors have been approved for your course: Various
Number of Credits Approved: 9.75

 

Medication Access and Training Expansion (MATE) Act 

This course is designed to meet the requirements outlined in the Medication Access and Training Expansion (MATE) Act. (Click here for more information.)
Number of hours: 9.75

 

Continuing Education Units (CEUs)

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 9.75 hours or 0.975 CEUs.

Available Credit

  • 9.75 AAPA Category 1 CME
  • 9.75 ACPE Contact Hours - Pharmacist
  • 9.75 ACPE Contact Hours - Pharmacist Technician
  • 9.75 AMA PRA Category 1 Credit™
  • 9.75 ANCC Contact Hours
    • 9.75 Wisconsin Responsible Opioid Prescribing Credit
    • 2.75 ANCC Pharmacotherapy Contact Hours
  • 9.75 University of Wisconsin–Madison Continuing Education Hours
    • 9.75 Approved for AMA PRA Category 1 Credit™
    • 9.75 Wisconsin Responsible Opioid Prescribing Credit

Cost:
$0.00
Please login or register to take this course.

This activity is in-person only. 

Program Questions

Email Kathleen Maher [email protected]

Questions about the ICEP Learning Portal

Email [email protected].

Program Changes

Emergency situations occasionally occur and may necessitate topic or speaker changes. The University of Wisconsin School of Medicine and Public Health and the University of Wisconsin–Madison ICEP reserve the right to alter or substitute a topic or speaker without prior notification.

Accessibility

We value inclusion and access for all participants and are pleased to provide reasonable accommodation for this event. Please email [email protected] as soon as you can make a reasonable accommodation request. 

Deadline for Materials and Claiming Credit

This course will close 45 days after the last day of the activity. To satisfy reporting obligations and ensure educational content remains compliant with accreditation standards, learners will not be able to claim credit or access course materials after this date.